Abiraterone could halve risk of prostate cancer death for some patients 23 Dec 2021 Adding abiraterone to the standard treatment for locally advanced prostate cancer, where the cancer has a high chance of spreading*, could halve the risk of death from the disease. Find out more Show/Hide
Abiraterone keeps men with prostate cancer at risk of spreading alive for longer 19 Sep 2021 Giving the drug abiraterone alongside standard hormone therapy helps men with high-risk prostate cancer, that has not spread elsewhere in the body, live longer. Find out more Show/Hide
The ICR responds to NICE’s recommendation not to approve abiraterone as first-line treatment for advanced prostate cancer 15 Jul 2021 The Institute of Cancer Research, London, is disappointed at the decision by NICE not to recommend abiraterone as a first-line NHS treatment for newly diagnosed, advanced prostate cancer. Find out more Show/Hide